Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025MedicineOpen Access

Identification of therapeutic targets for rheumatic heart valve disease based on systematic druggable genome wide Mendelian randomization

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWeihua ShiJZJing-Chang ZhangZXZhitao Xie

Discussion

Loading...

Member takes

Overview

Mendelian randomization identifies 13 potential drug targets for rheumatic heart valve disease, suggesting pathways for new therapies.

Key Points

  • Thirteen potential therapeutic targets for rheumatic heart valve disease were identified, providing new avenues for drug development.
  • Among the targets, LILRB1 showed promise with a protective effect in rheumatic heart valve disease (odds ratio of 0.833).
  • The study utilized a 2-sample Mendelian randomization approach to assess the impact of druggable gene expression on disease risk.
  • Insights from Gene Ontology analysis revealed that the targets are linked to immune and inflammatory responses.

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/68de79615b556a9128e1a80ehttps://doi.org/10.1097/md.0000000000044531
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mendelian randomization identifies multiple immune cell surface markers as potential causal contributors and drug targets in rheumatoid arthritis2026
  2. 2Clinical significance and regulatory mechanism of miR-134-5p in rheumatic heart disease2025
  3. 3Rheumatic Heart Disease2026
  4. 4Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a pQTL-based Mendelian randomization and colocalization analysis2025
  5. 5Decoding rheumatoid arthritis: Biomarker identification and immune profiling via bioinformatics and Mendelian randomization2025 · 1 citations